Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 329-337 |
| Number of pages | 9 |
| Journal | Clinical Pharmacology & Therapeutics |
| Volume | 106 |
| Issue number | 2 |
| Early online date | 23 Apr 2019 |
| DOIs | |
| Publication status | Published - Aug 2019 |
Fingerprint
Cite this
}
Diabetes : Is there a future for Pharmacogenomics guided treatment? / Pearson, Ewan (Lead / Corresponding author).
In: Clinical Pharmacology & Therapeutics, Vol. 106, No. 2, 08.2019, p. 329-337.Research output: Contribution to journal › Article
TY - JOUR
T1 - Diabetes
T2 - Is there a future for Pharmacogenomics guided treatment?
AU - Pearson, Ewan
N1 - Funding: Wellcome Trust New Investigator Award 102820/Z/13/Z .
PY - 2019/8
Y1 - 2019/8
N2 - Diabetes is a disease defined on the basis of hyperglycaemia. There are monogenic forms of diabetes where defining the genetic cause has a dramatic impact on treatment ‐ with patients being able to transition from insulin to sulphonylureas. However, the majority of diabetes is type 2 diabetes. This review outlines the robust evidence accrued to date for pharmacogenetics of metformin, sulphonylureas, thiazolidinediones and DPP4 inhibitors, but highlights that these variants will only be of clinical utility when the genotype is already known at the point of prescribing. The future of pharmacogenetics in diabetes and other common complex disease relies on a paradigm shift ‐ that of pre‐emptive panel genotyping and use of clinical decision support tools to assimilate this genetic information with other clinical phenotypic data and to present this information simply to the prescriber. Given the recent dramatic fall in genotyping costs, this future is not far off.
AB - Diabetes is a disease defined on the basis of hyperglycaemia. There are monogenic forms of diabetes where defining the genetic cause has a dramatic impact on treatment ‐ with patients being able to transition from insulin to sulphonylureas. However, the majority of diabetes is type 2 diabetes. This review outlines the robust evidence accrued to date for pharmacogenetics of metformin, sulphonylureas, thiazolidinediones and DPP4 inhibitors, but highlights that these variants will only be of clinical utility when the genotype is already known at the point of prescribing. The future of pharmacogenetics in diabetes and other common complex disease relies on a paradigm shift ‐ that of pre‐emptive panel genotyping and use of clinical decision support tools to assimilate this genetic information with other clinical phenotypic data and to present this information simply to the prescriber. Given the recent dramatic fall in genotyping costs, this future is not far off.
U2 - 10.1002/cpt.1484
DO - 10.1002/cpt.1484
M3 - Article
C2 - 31012484
VL - 106
SP - 329
EP - 337
JO - Clinical Pharmacology & Therapeutics
JF - Clinical Pharmacology & Therapeutics
SN - 0009-9236
IS - 2
ER -